A dynamic model to predict sustained virological response to combination peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) therapy in patients with chronic hepatitis C.

被引:0
作者
Ferenci, P
Fried, MW
Chaneac, M
机构
[1] Univ Vienna, A-1010 Vienna, Austria
[2] Univ N Carolina, Chapel Hill, NC 27515 USA
[3] Roche Diagnost, Basel, Switzerland
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
995
引用
收藏
页码:635A / 635A
页数:1
相关论文
empty
未找到相关数据